Concourse Financial Group Securities, Inc. Scynexis Inc Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$1.27 - $2.23 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.4 - $2.77 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.39 - $2.21 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.56 - $2.24 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.93 - $3.64 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.93 - $3.64 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$2.38 - $3.67 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.15 - $3.0 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.46 - $2.94 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.83 - $2.93 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.77 - $3.87 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.56 - $6.66 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.94 - $7.69 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$5.3 - $7.89 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$6.5 - $9.97 $0 - $0
Q1 2021 May 13, 2021	BUY	$6.93 - $9.63 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$4.28 - $7.87 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$4.37 - $7.48 $0 - $0

Others Institutions Holding SCYX

# of Institutions

Shares Held

13.7M

Call Options Held

21.9K

Put Options Held

2.6K

Federated Hermes, Inc. Pittsburgh, PA

3.6M
Shares

$4.31 Million
0.01% of portfolio
Kingdon Capital Management, L.L.C. New York, NY

2.24M
Shares

$2.68 Million
0.4% of portfolio
Vanguard Group Inc Valley Forge, PA

1.69M
Shares

$2.02 Million
0.0% of portfolio
Avidity Partners Management LP Dallas, TX

1.45M
Shares

$1.74 Million
0.13% of portfolio
Amh Equity LTD

600K
Shares

$720,000
1.24% of portfolio

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $39.2M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account